Effect of methionine-35 oxidation on the aggregation of amyloid-β peptide  by Friedemann, Merlin et al.








Medicinjournal homepage: www.elsevier.com/locate/bbrepEffect of methionine-35 oxidation on the aggregation of amyloid-β
peptide
Merlin Friedemann, Eneken Helk, Ann Tiiman 1, Kairit Zovo, Peep Palumaa, Vello Tõugu n
Department of Gene Technology, Tallinn University of Technology, Akadeemia tee 15, 12618 Tallinn, Estoniaa r t i c l e i n f o
Article history:
Received 18 June 2015
Received in revised form
22 July 2015
Accepted 28 July 2015






08/& 2015 The Authors. Published by Elsevie
viations: Aβ, Alzheimer's amyloid peptide; A
,3-hexaﬂuoro-2-propanol; OS, oxidative stress
T, Thioﬂavin T
esponding author.
ail address: vello.tougu@ttu.ee (V. Tõugu).
esent address: Department of Clinical Neuros
e CMM L8:01, Karolinska Institutet, Stockholma b s t r a c t
Aggregation of Aβ peptides into amyloid plaques is considered to trigger the Alzheimer’s disease (AD),
however the mechanism behind the AD onset has remained elusive. It is assumed that the insoluble Aβ
aggregates enhance oxidative stress (OS) by generating free radicals with the assistance of bound copper
ions. The aim of our study was to establish the role of Met35 residue in the oxidation and peptide
aggregation processes. Met35 can be readily oxidized by H2O2. The ﬁbrillization of Aβ with Met35 oxi-
dized to sulfoxide was three times slower compared to that of the regular peptide. The ﬁbrils of regular
and oxidized peptides looked similar under transmission electron microscopy. The relatively small in-
hibitory effect of methionine oxidation on the ﬁbrillization suggests that the possible variation in the Met
oxidation state should not affect the in vivo plaque formation. The peptide oxidation pattern was more
complex when copper ions were present: addition of one oxygen atom was still the fastest process,
however, it was accompanied by multiple unspeciﬁc modiﬁcations of peptide residues. Addition of
copper ions to the Aβ with oxidized Met35 in the presence of H2O2, resulted a similar pattern of non-
speciﬁc modiﬁcations, suggesting that the one-electron oxidation processes in the peptide molecule do
not depend on the oxidation state of Met35 residue. Thus, it can be concluded that Met35 residue is not a
part of the radical generating mechanism of Aβ–Cu(II) complex.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Alzheimer's disease (AD) is characterized by progressive neu-
ronal death and the accumulation of protein aggregates in certain
brain areas. The aggregation of amyloid-β (Aβ) peptide into ex-
tracellular amyloid plaques is identiﬁed as the key molecular event
in AD, however, the molecular cascade leading to the death of
neurons remains elusive. The increase of oxidative stress (OS) le-
vels in certain brain areas is also characteristic to the disease and
this increase is assumed to be an early event in AD [1,2]. The major
risk factor for the pathogenesis of AD is aging and according to the
free radical hypothesis the major cause of aging is the accumula-
tion of ROS and the accumulation of oxidative damage [3]. The
relationship between OS and AD progression is a complex one:
elevated levels of OS can be both, the risk factor and the con-
sequence of AD progression [4,5]. The toxicity of Aβ aggregates isr B.V. This is an open access article
D, Alzheimer's disease; HFIP,
; ROS, reactive oxygen spe-
cience, Center for Molecular
, 17176, Sweden.assumed to arise from their ability to generate free radicals [6,7],
which depends on the presence of copper ions.
Considering the involvement of Aβ in oxidative processes, the
Met35 is one of the most intriguing amino acid residues in the
peptide molecule. Met35 has the most easily oxidized side chain in
the peptide and it is partially oxidized in post mortem amyloid
plaques [8,9]. There has been many speculations about the role of
Met35 in the formation of amyloid plaques and peptide toxicity: it
has been suggested that Aβmediated generation of ROS is initiated
by the Met 35 residue [10]. On the other hand, a particular func-
tion in neuroprotection is also proposed for Met35 due to the
antioxidant character of the thioether group [11,12]. The sugges-
tions about the involvement of Met35 in toxic mechanisms is
supported by the observation that Met35 oxidation state is critical
for Aβ synaptotoxicity – the oxidized form was clearly less toxic
that the reduced one [13]. It has been shown that oxidation of
Met35 reduces the Aβ42 toxicity in human neuroblastoma cells
[14,15], however, the substitution of Met35 to valine and norleu-
cine had no effect on the toxicity of Aβ [16,17].
Methionine residues can be oxidized by two different me-
chanisms [18]. First, they can be spontaneously oxidized to me-
thionine sulfoxide in a two electron process by some oxidants such
as H2O2 and molecular oxygen. This oxidation pathway can be
considered relatively benign since no reactive oxygen species orunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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is a common reaction in living organism and the oxidation can be
reversed by the methionine sulfoxide reductases, enzymes that
reduce the sulfoxide and are an essential part of redox detox-
iﬁcation mechanisms in the living organisms. Methionine oxida-
tion to sulfoxide is demonstrated to inhibit ﬁbril formation [12]
and this observation has also lead to various speculations about
the essential role of the oxidation of Met35 in AD. The sulfoxide
can be further oxidized to sulfone, however, this reaction does not
occur in physiological environments.
From the viewpoint of AD progression the second mechanism,
one-electron oxidation of methionine to a highly reactive radical
cation intermediate, is more intriguing. The single-electron me-
chanism can be catalyzed by copper ions that can have an essential
role in AD etiology since they bind to Aβ with high afﬁnity and
enhance its aggregation whereas the electrochemically active
copper ions buried within the aggregates can generate ROS and
cause OS [19,20]. An intriguing question is whether the radical
cation generated from Met35 is an essential intermediate in the
pathway of Aβ generated oxidative stress or is this just a supple-
mentary process that does not contribute to ROS generation and
OS. In order to answer these questions we studied the kinetics and
products of the oxidation of Aβ by H2O2 in the presence and ab-
sence of copper ions as the catalysts of one electron oxidation
processes. Methionine oxidation slightly decreased the rate of in
vitro ﬁbrillization of the Aβ peptides but did not changed its ability
to catalyze the formation of ROS.2. Materials and methods
2.1. Materials
Lyophilized Aβ40 and Aβ42 peptides (ultra pure, recombinant)
NaOH salts or HFIP forms were purchased from rPeptide (Athens,
USA). HEPES, Ultrapure, MB Grade was from USB Corporation
(Cleveland, USA), 1,1,1,3,3,3-hexaﬂuoro-2-propanol (HFIP) and
Thioﬂavin T (ThT) were from Sigma Aldrich (St. Louis, USA). NaCl
was extra pure from Scharlau (Barcelona, Spain). All solutions
were prepared in fresh MilliQ water.
2.2. Sample preparation
Stock solution of Aβ peptides was prepared as follows: 1 mg of
the peptide was dissolved in HFIP at a concentration 500 μM to
disassemble preformed aggregates [21]. The solution was divided
into aliquots, HFIP was evaporated in vacuum and the tubes with
the peptide ﬁlm were kept at 80 °C until used. Before using the
Aβ HFIP ﬁlm was dissolved in water containing 10 mM NaOH at a
concentration of 10–20 μM. After 5 min incubation the Aβ stock
solution was dissolved with buffer and used for experiments.
2.3. Fluorescence spectroscopy
Fluorescence spectra were collected on a Perkin-Elmer LS-45
ﬂuorescence spectrophotometer equipped with a magnetic stirrer.
Fibrillation was monitored using ThT ﬂuorescence. If not otherwise
stated, fresh Aβ stock solution was diluted in 20 mM HEPES and
100 mM NaCl, pH 7.4 containing 3.3 μM of ThT to a ﬁnal con-
centration of 5 μM. 400 μl of each sample was incubated at 40 °C if
not otherwise stated. ThT ﬂuorescence was measured at 480 nm
using excitation at 445 nm.
2.4. Data analysis and kinetics of ﬁbril formation
The kinetics of Aβ ﬁbrillation could be described as sigmoidcurves and the aggregation parameters were determined by ﬁtting
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where A1 is the initial ﬂuorescence level, A2 corresponds to the
ﬂuorescence at maximal ﬁbrillation level, t0 is the time t when
ﬂuorescence is reached half maximum and k is the rate constant of
ﬁbril growth.2.5. Transmission electron microscopy (TEM)
An aliquot of 5 μl of sample was loaded on a Formvar-coated,
carbon-stabilized copper grid (300 mesh from Ted Pella Inc.,
Redding CA). After 1 min, the excess solution was drained off using
a Whatman ﬁlter paper. The grid was brieﬂy washed and nega-
tively stained with 5 μl of 2% uranyl acetate. The grid was air-dried
and then viewed on a Tecnai G2 BioTwin transmission electron
microscope (FEI, Japan) operating with an accelerator voltage of
80 kV. Typical magniﬁcations ranged from 20,000 to 60,000 .2.6. Kinetics of Aβ oxidation
20 Aβ M of alkaline Aβ solution in 0.1% NaOH was diluted with
equal volume of 0.1 M phosphate buffer containing hydrogen
peroxide (H2O2) and Cu(II). Final concentrations of H2O2 was 1%
and the concentrations of copper ions were 0.1 and 10 mM. The
kinetics of Aβ oxidation and the disappearance of monomers from
the solution were monitored with matrix-assisted laser deso-
rption/ionization mass spectrometry (MALDI MS) using the energy
absorbing matrix α-cyando-4-hydroxycinnamic acid (CHCA) [22].
Matrix CHCA was dissolved in 60% acetonitrile and 0.3% tri-
ﬂuoroacetic acid to a concentration of 10 mg/ml, containing
0.3 mM bovine insulin as an internal standard. Samples were mixed
with matrix (1:3 ratio of sample: matrix) and 1 ml was spotted on
the MALDI plate. MALDI MS spectra were acquired by Voyager-
DE™ STR Biospectrometry Workstation in linear mode using auto-
mated program. Instrument parameter/settings: accelerating vol-
tage 25,000 V; mass range (m/z) 1500–10,000 Da; delay time
485 ns; grid voltage 93%; laser intensity 2200 V, shots per spec-
trum – 40; accumulated spectrum – 10.
The site of oxidation was determined by sequencing the oxi-
dized peptide on ESI-MS. 10 mM Ab42 in 100 mM ammonium
acetate buffer (pH 7.5) was injected into the electrospray ion
source of QATAR Elite ESI-Q-TOF MS instrument (Applied Biosys-
tems) by a syringe pump at 7 ml/min. ESI MS spectra were recorded
for 5 min in them/z region from 300 to 1500 Da with the following
instrument parameters: ion spray voltage 5500 V; source gas 45 l/
min; curtain gas 20 l/min; declustering potential 45 V; focusing
potential 260 V; detector voltage 2450 V; collision energy 50 V;
collision gas 5 l/min; precursor-ion mode.
Sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) was performed using Mini-PROTEAN Tetra System (Bio-
Rad). Samples were mixed with loading buffer (0.36 M Bistris,
0.053 M Bicine, 15% glycerol, 1% SDS, 0.004% bromophenol blue),
maintained at room temperature, applied to Bicine–Tris 15%T/5%C
gel and resolved in a cathode buffer with 0.25% SDS (110 V) [23].
Gels were ﬁxated in glutaraldehyde/borate buffer solution for
45 minutes and stained with silver according to a protocol [24].
Fig. 1. Oxidation of Aβ42 peptide with H202 in the absence of copper ions.
(A) MALDI MS spectra of Aβ42 incubated in 20 mM HEPES at pH 7.3 in the presence
of 1% H202. Samples were taken at time intervals shown in the legend; (B) kinetics
of oxidation, ●  1% H202, Ο-control; k¼(0.1147 0.012) min1.
M. Friedemann et al. / Biochemistry and Biophysics Reports 3 (2015) 94–99963. Results
3.1. Oxidation of Met35 by H2O2
The oxidation of Aβ42 by H2O2 was studied by MALDI mass
spectrometry. Fig. 1 shows that the peptide was easily oxidized in
the presence of 200 mM H2O2. During the incubation with hy-
drogen peroxide the molecule mass of the peptide increased by 16
units and the process was almost complete within 40 min. The
oxidation of Met35 residue was conﬁrmed by ESI MS/MSsequencing of the resulting oxidized peptide (Supplementary
Fig. 1). Kinetic analysis of the MALDI MS data (Fig. 1B) showed that
the disappearance of reduced Aβ and the increase of AβMet35ox
followed the ﬁrst order kinetics. In the absence of copper ions
AβMet35ox was the only product of the oxidation: no side pro-
ducts were detected in a signiﬁcant amount.
The oxidation pattern of Aβ in the presence of copper ions was
more complex. As the copper complex of Aβ42 tends to form a
precipitate during 30 min of incubation [25] the oxidation in the
presence of copper ions was studied using Aβ40 peptide. Fig. 2
shows that the addition of a single oxygen atom was still the
fastest process; however, the widening of the peptide peak in MS
showed that subsequently a large number of non-speciﬁc mod-
iﬁcations (oxygen additions and elimination) reactions in the Aβ
molecule occurred. When Cu(II) ions were added to the reaction
mixture after the oxidation of Met35 by H2O2 (Fig. 2B), a similar
pattern of nonspeciﬁc modiﬁcations was observed, suggesting that
the single-electron oxidation processes in Aβ does not depend on
the oxidation state of Met35. In principle, a peptide dimer can also
form by dityrosine crosslinking during peptide oxidation. SDS
PAGE (Fig. 2C for Aβ 40 and Supplementary Fig. 2 for Aβ42) shows
that peptide dimers do not form under our experimental condi-
tions, peaks of dimers and trimers were also not detected by
MALDI MS.
3.2. Fibrillization of AβMet35ox
The ﬁbrillization of Aβ was studied under the conditions of
intensive agitation where the fast ﬁbrillization of the peptide
proceeds with good reproducibility [25,26]. Incubation of un-
puriﬁed oxidized peptide under these conditions did not reveal an
increase in ThT ﬂuorescence; however, the peptide peak in the
MALDI MS spectrum disappeared showing ﬁbrillation [22] and in a
TEM image typical non-matured ﬁbrils were observed. As the
oxidizing agent can interfere with the ThT based detection method
we repeated the experiments after removing the oxidizing solu-
tion by lyophilization and redissolving the peptide in HEPES buffer.
Both oxidized peptides, Aβ42 and Aβ40, showed a typical sig-
moidal ﬁbrillization curve (Fig. 3A and B), whereas the value of the
ﬁbrillization rate constant, k, was threefold lower than that of the
regular peptide. The lag-phase for the oxidized peptide was also
longer however, the resulting ﬁbrils look similar in TEM (Fig. 3C).4. Discussion
In this work we studied the oxidation of Aβ in the presence of
two physiologically relevant redox-active compounds H2O2 and
copper ions. Low concentrations of H2O2 are always present in
living organisms and take part in various redox processes; copper
ions bind to Aβ with high afﬁnity in a catalytically active form and
are present in amyloid plaques. The aim of the study was to es-
tablish the role of the Met35 residue in the oxidation and peptide
aggregation processes. In the absence of copper ions the Met35
residue in Aβ molecule was readily oxidized to sulfoxide (Fig. 1
and Supplementary Fig. 1) and this was almost the only mod-
iﬁcation observed. Met35 oxidation only slightly inhibited Aβ ﬁ-
brillization, thus, we suggest that the possible variation in the Met
oxidation state should not have a large effect on the plaque for-
mation in vivo. The amyloid ﬁbril formation is a complex auto-
catalytic process and the ﬁbrillization in agitated solutions models
the ﬁbril growth phase, but not the initiation of the ﬁbrillization
process or the formation of the protoﬁbrils and ﬁrst ﬁbrils.
In the presence of copper ions that form a high afﬁnity complex
with Aβ, the oxidation was more complex, the addition of the ﬁrst
oxygen was still the fastest process, however, it was accompanied
Fig. 2. Oxidation of Aβ40 peptide with H202 in the presence of copper ions. MALDI MS spectra of Aβ42 incubated in the presence of 1% H202 at pH 7.3 in 20 mM HEPES.
Samples were taken at time intervals shown in the legend; A – native peptide; B – peptide was oxidized with H202 for 40 min before adding copper ions. C-SDS Page of Aβ40:
Control, untreated peptide, Aβox, oxidized with H202 in the absence of copper ions and Aβ oxþCu refers to oxidized peptide treated with H202 in the presence of copper ions
for 3 h.
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Met35 oxidation had no effect on the oxidative behavior of Aβ
complex with copper ions – when Met35 was oxidized in the
absence of copper, the addition of copper still lead to the ap-
pearance of diverse spectrum of oxidized peptides. These mod-
iﬁcations may include the oxidation of His and Phe residues in Aβ
and Glu 1 decarboxylation observed in the presence of oxygen and
ascorbic acid [27]. Thus, it can be concluded that Met35 residue is
not a part of the radical generating mechanism of the Aβ–Cu(II)
complex.
The oxidation state of Met35 enhances the toxicity of the ar-
tiﬁcial truncated Aβ25-35, which affects mitochondria [28].
However, the high toxicity of this derivative is dependent on the
C-terminal position of methionine and does not apply to the
longer Aβ variants such as 25–36 [29], thus, this process is notrelated to the toxic effect of the full-length Aβ and amyloid pla-
ques. It should also be noted that we did not observed the for-
mation of potentially highly toxic Aβ dimers under our experi-
mental conditions e. g. the oxidative dimerization of Aβ due to
tyrosine crosslinking did not occur at considerably higher con-
centrations of the peptide and H2O2 than those in the brain.
However, the oxidative dimerization of Aβ in vivo can be catalyzed
by enzymes [30]. It should also be noted that the Aβ “dimers” from
biological material have never been analyzed chemically e. g. they
are not necessarily dimers, but they can be longer peptides con-
taining the Aβ sequence [31].
Methionine added to the environment also does not serve as a
reducing agent for the Cu(II)–Aβ complex [32], thus, it can be
concluded that from the viewpoint of redox ability and ﬁbril for-
mation the possible oxidation of Met35 residue is not an
Fig. 3. Fibrillization of Aβ peptides with reduced and oxidized Met35 residues at pH 7.3, 20 mM HEPES, 100 mM NaCl, 5 μM ThT. A – Fibrillization of Aβ42: 4 μM Aβ42 37 °C:
Curves correspond to k¼(1.3070.02) min1, tlag¼11.8 min1 for reduced and k¼(3.8370.05) min1, tlag¼24.9 min1 for Met35ox peptide. B-Fibrillization of Aβ40: 5 μM
Aβ40; 50 °C; Curves correspond to k¼(3.9270.09) min1, tlag¼22.6 min1 for reduced peptide and k¼(14.170.3) min1, tlag¼14.0 for the oxidized peptide; C-TEM images
of Aβ40 ﬁbrils, left Aβ40ox; right – Aβ40 control.
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in AD pathogenesis due to putative interactions in the biological
systems. It has been shown that in a Caenorhabditis elegans model
of inclusion body myositis the knockout of MSRA-1 reduces the
aggregation of Aβ into insoluble aggregates [33], however in this
case the aggregation is intracellular. Even small differences in the
peptide aggregation properties may be crucial in triggering the
molecular events leading to the disease, however the lower amy-
loidogenity and the unaffected ability to catalyze redox reactions
when bound to copper ions suggest that Met35 oxidation is most
likely not essential in AD. Recently it has been shown that Aβ with
oxidized Met 35 that does not cross the neuronal plasma mem-
brane and is not uploaded from the extracellular space has no
effect on synaptic plasticity when applied extracellularly [34].Acknowledgments
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